| Drug Name: | LPC-233 |
| C: | 19 |
| H: | 18 |
| F: | 2 |
| N: | 2 |
| O: | 4 |
| Iupac Name: | 4-(4-cyclopropylbuta-1,3-diynyl)-N-[(2''S'',3''S'')-4,4-difluoro-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]benzamide |
| Cas Number: | 2142075-09-8 |
| Pubchem: | 132060142 |
| Pdb Ligand: | UFX |
| Smiles: | C[C@]([C@@H](C(=O)NO)NC(=O)C1=CC=C(C=C1)C#CC#CC2CC2)(C(F)F)O |
| Stdinchi: | 1S/C19H18F2N2O4/c1-19(26,18(20)21)15(17(25)23-27)22-16(24)14-10-8-13(9-11-14)5-3-2-4-12-6-7-12/h8-12,15,18,26-27H,6-7H2,1H3,(H,22,24)(H,23,25)/t15-,19+/m1/s1 |
| Stdinchikey: | NPTNDHDCCLLFJE-BEFAXECRSA-N |
LPC-233 is an experimental antibiotic drug. It acts as a potent and selective inhibitor of the bacterial enzyme UDP-3-O-acyl-N-acetylglucosamine deacetylase (LpxC), which is important for the production of Lipid A, a key component of the cell membrane of Gram-negative bacteria. Various inhibitors of LpxC have been developed but none have yet progressed into clinical trials in humans, mostly because of off-target cardiovascular toxicity.[1] [2] [3] LPC-233 is one of the most advanced drugs of this type in preclinical testing, showing activity against several pathogens of concern such as multidrug-resistant Pseudomonas aeruginosa and carbapenem resistant Enterobacter strains, and with no cardiovascular toxicity evident in testing on mice and dogs.[4] [5]